
Janux Therapeutics Announces Positive Initial Phase 1 Data for JANX011 in Healthy Volunteers, Supporting Planned Development in Patients with Autoimmune Disease
Janux Therapeutics, Inc. a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, announced initial clinical results from the Phase 1 study of JANX011 in healthy volunteers and outlined its planned clinical development strategy in autoimmune diseases. JANX011 is the first program from Janux’s proprietary Adaptive Immune Response Modulator (ARM) platform to enter clinical development. The ARM platform is designed to selectively recruit a defined T-cell subset to drive deep and sustained target-cell depletion while limiting broad T-cell activation.
Following one subcutaneous dose without step-up dosing, JANX011 demonstrated deep B-cell depletion, Grade 1-only cytokine release syndrome (CRS), and selective activation of the intended TRBV6-expressing T-cell subset. Together, these findings provide initial human clinical validation of ARM and establish a strong foundation for advancing JANX011 in autoimmune disease.
This marks an important step forward for Janux,” said David Campbell, Ph.D., President and Chief Executive Officer of Janux. “The results give us a strong foundation to advance JANX011 in autoimmune disease and provide the first human validation of ARM. We see an opportunity to build significant value both through JANX011 and by extending ARM across additional targets and indications.
Initial Phase 1 Clinical Results
The Phase 1 study evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics of JANX011 in healthy volunteers. The initial dataset includes 25 participants across five single-ascending-dose cohorts ranging from 30 µg to 3 mg. JANX011 was administered subcutaneously and without step-up dosing. The study was designed to characterize human pharmacology and establish an initial activity and tolerability profile to inform subsequent development in autoimmune patient studies. The data presented reflect a November 2, 2026 data cutoff.
JANX011 Clinical Development Strategy
Based on the initial clinical findings, Janux plans to advance JANX011 into autoimmune patient studies, initially in immune thrombocytopenia (ITP) and rheumatoid arthritis (RA), with study initiations targeted for the first and second halves of 2027, respectively.
ITP and RA were selected as initial indications to establish clinical proof of concept and characterize JANX011’s potentially differentiated clinical profile. ITP provides an early, objective measure of clinical activity through platelet response, while RA provides an opportunity to develop JANX011 in a larger, established autoimmune indication to further characterize dose, regimen, durability and clinical activity. Across both indications, Janux aims to evaluate the potential of JANX011 to deliver meaningful clinical benefit to patients through targeted B-cell depletion with a favorable safety profile and convenient dosing regimen.
The healthy-volunteer study established a strong starting point for patient development and further optimization of dose and regimen.
About JANX011
JANX011 is an investigational CD19-targeted bispecific T-cell engager and the first clinical-stage candidate from Janux’s proprietary Adaptive Immune Response Modulator (ARM) platform. It is designed to selectively engage T cells through the conserved TRBV6 domain rather than CD3 and is being developed for the potential treatment of autoimmune diseases.
Initial Human Validation of the ARM Platform
The ARM platform is designed to selectively recruit a defined T-cell subset rather than broadly engage T cells through CD3. Initial human results with JANX011 link selective TRBV6 T-cell activation with deep B-cell depletion and Grade 1-only CRS, supporting the ARM design. Janux believes these findings provide a foundation for extending ARM across additional targets and formats.
Investor Webcast Information
Janux will host an investor webcast today, November 9, 2026, at 8:30 a.m. ET to review the initial JANX011 clinical results and discuss its planned autoimmune development strategy. The webcast will include a management presentation followed by a live question-and-answer session.
The presentation and webcast will be accessible through the Events and Presentations section of the Janux website.
Analysts and investors wishing to participate in the live Q&A may use the participant callback link to enter their contact information and receive an automated call connecting them to the event. Alternatively, participants may dial 877-346-6112 (U.S. and Canada toll-free) or +1-848-280-6350 (international).
About Janux Therapeutics
Janux is a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms.
Janux’s lead clinical candidate, JANX007, is a PSMA-targeted TRACTr being investigated in a Phase 1 clinical trial in patients with metastatic castration-resistant prostate cancer (mCRPC). The Company is also advancing additional PSMA-targeted programs, including JANX014, a double-masked PSMA-TRACTr being evaluated in a Phase 1 clinical trial, and JANX013, a CD28 co-stimulatory TRACIr designed for combination with JANX007 and being evaluated in a Phase 1 clinical trial.









